Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options
July 2015
Click for full info +Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options
 |
17 July 2015
|
In this Press Release:
Health Risk(s):
HIV
Product Type(s):
Microbicides
MPTs
Vaccines
Topic(s):
Advocacy
Funding